Published in J Clin Pharmacol on October 20, 1977
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther (1981) 69.83
Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med (1975) 7.60
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet (2000) 4.42
Clinical pharmacokinetics (second of two parts). N Engl J Med (1975) 3.17
Use of benzodiazepines in anxiety disorders. N Engl J Med (1993) 3.12
Drug therapy: drug disposition in old age. N Engl J Med (1982) 3.04
Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet (2000) 2.94
Midazolam: pharmacology and uses. Anesthesiology (1985) 2.89
Sensitivity to triazolam in the elderly. N Engl J Med (1991) 2.73
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Intramuscular injection of drugs. N Engl J Med (1976) 2.20
Impairment of antipyrine clearance in humans by propranolol. Circulation (1978) 2.18
Diazepam disposition determinants. Clin Pharmacol Ther (1980) 2.16
Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology (1984) 2.14
Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther (1977) 2.05
Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry (2010) 2.05
Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry (2009) 2.03
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos (2000) 1.87
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol (1996) 1.86
Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry (1990) 1.84
Automated gas chromatography for studies of midazolam pharmacokinetics. Anesthesiology (1981) 1.78
Sea urchin (lytechinus pictus) late-stage histone H3 and H4 genes: characterization and mapping of a clustered but nontandemly linked multigene family. Cell (1982) 1.69
Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol (1978) 1.65
TULP1 mutation in two extended Dominican kindreds with autosomal recessive retinitis pigmentosa. Nat Genet (1998) 1.60
Clinical pharmacokinetics of quinidine. Clin Pharmacokinet (1980) 1.59
Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol (1981) 1.59
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry (1998) 1.56
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA (1973) 1.54
Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs (1974) 1.54
Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev (1978) 1.54
Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther (2001) 1.52
Differential actions of chlordiazepoxide and oxazepam on hostility. Arch Gen Psychiatry (1968) 1.50
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos (2001) 1.47
Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther (1980) 1.47
Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther (1994) 1.44
Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J (1977) 1.43
Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med (1980) 1.42
Genome-wide association study of Tourette's syndrome. Mol Psychiatry (2012) 1.42
A retrospective study of children's perceptions of participation as clinical research subjects in a minimal risk study. J Dev Behav Pediatr (2001) 1.42
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol (1997) 1.42
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther (2000) 1.41
Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry (1993) 1.41
Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam. J Chromatogr (1978) 1.41
Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry (2000) 1.40
Drug transporters in psychopharmacology--are they important? J Clin Psychopharmacol (2000) 1.40
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth (1983) 1.39
MAOIs and hypertension. J Clin Psychopharmacol (1992) 1.39
Drug therapy. Current status of benzodiazepines. N Engl J Med (1983) 1.39
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol (1996) 1.39
Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci (1979) 1.37
Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. Cardiology (1984) 1.37
Effect of midazolam infusion and flumazenil administration on epinephrine arrhythmogenicity in dogs anesthetized with halothane. Anesthesiology (1993) 1.37
Apparent mtDNA heteroplasmy in Alzheimer's disease patients and in normals due to PCR amplification of nucleus-embedded mtDNA pseudogenes. Proc Natl Acad Sci U S A (1997) 1.36
Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry (1990) 1.35
Lorazepam kinetics in the elderly. Clin Pharmacol Ther (1979) 1.35
Pharmacokinetic and clinical implications of quinidine protein binding. J Pharm Sci (1979) 1.34
Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. J Clin Pharmacol (1978) 1.33
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther (1999) 1.32
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J (2002) 1.31
Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet (1981) 1.31
Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther (1978) 1.29
Clinical implications of benzodiazepine pharmacokinetics. Am J Psychiatry (1977) 1.29